<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> properties of <z:chebi fb="0" ids="6801">metformin</z:chebi> are mediated through its ability to activate the <z:chebi fb="47" ids="16027,28971">AMP</z:chebi>-activated protein kinase (AMPK) </plain></SENT>
<SENT sid="1" pm="."><plain>Activation of AMPK can suppress <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> formation and inhibit cell growth in addition to lowering blood <z:chebi fb="105" ids="17234">glucose</z:chebi> levels </plain></SENT>
<SENT sid="2" pm="."><plain>We tested the hypothesis that <z:chebi fb="0" ids="6801">metformin</z:chebi> reduces the risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in people with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>RESEARCH DESIGN AND METHODS: In an observational cohort study using record-linkage databases and based in Tayside, Scotland, U.K., we identified people with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> who were new users of <z:chebi fb="0" ids="6801">metformin</z:chebi> in 1994-2003 </plain></SENT>
<SENT sid="4" pm="."><plain>We also identified a set of diabetic comparators, individually matched to the <z:chebi fb="0" ids="6801">metformin</z:chebi> users by year of <z:mp ids='MP_0002055'>diabetes</z:mp> diagnosis, who had never used <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>In a survival analysis we calculated hazard ratios for diagnosis of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, adjusted for baseline characteristics of the two groups using Cox regression </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> was diagnosed among 7.3% of 4,085 metformin users compared with 11.6% of 4,085 comparators, with median times to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> of 3.5 and 2.6 years, respectively (P &lt; 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>The unadjusted hazard ratio (95% CI) for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> was 0.46 (0.40-0.53) </plain></SENT>
<SENT sid="8" pm="."><plain>After adjusting for sex, age, BMI, A1C, deprivation, smoking, and other drug use, there was still a significantly reduced risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> associated with <z:chebi fb="0" ids="6801">metformin</z:chebi>: 0.63 (0.53-0.75) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: These results suggest that <z:chebi fb="0" ids="6801">metformin</z:chebi> use may be associated with a reduced risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>A randomized trial is needed to assess whether <z:chebi fb="0" ids="6801">metformin</z:chebi> is protective in a population at high risk for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
</text></document>